Leaps by Bayer
Leaps by Bayer is the impact-focused corporate venture capital arm of Bayer AG, founded in 2015 to invest off the company balance sheet in transformational biotechnologies across human health and agriculture. It backs and co-founds companies pursuing ten defined breakthrough goals (the leaps), such as regenerating lost tissue, curing genetic diseases and reducing the environmental impact of farming. The unit has deployed more than USD 1.9 billion across 60-plus ventures, often co-founding companies (BlueRock, Century, Joyn Bio, Oerth Bio, Unfold) alongside partners like Versant, Ginkgo Bioworks, Temasek and Arvinas. Several holdings have been absorbed into Bayer (BlueRock) or exited via trade sale and IPO. It is led by Juergen Eckhardt and operates from Berlin and the United States as an evergreen strategic investor rather than a fixed-life fund.
Key facts
Recent exits
Coverage notes
1 fund tracked, 56 portfolio companies (47 active · 9 realized). Verified weekly from public filings and deal announcements.
Sector breakdown
56 companiesFunds & portfolio
Every fund Leaps by Bayer has raised, with its portfolio companies. Hand-checked from public filings.
Leaps by BayerEvergreenActive2015 · 11yr€1.8B47 active · 9 realized
Unrealized
47 held| Company | Sector | Geo | Entry |
|---|---|---|---|
| Biotech | Singapore | 2023 | |
| HealthTech |  Germany | 2021 | |
| AgTech |  US | 2022 | |
| Biotech | US | 2022 | |
| FoodTech | US | 2021 | |
| Healthcare | US | 2020 | |
| AgTech | US | 2021 | |
| Biotech | US | 2021 | |
| Biotech | US | 2026 | |
| Biotech | US | 2022 | |
| AgTech | Canada | 2023 | |
| Pharma | China | 2024 | |
| Biotech | US | 2021 | |
| Biotech | US | 2019 | |
| ClimateTech | US | 2021 | |
| HealthTech | US | 2021 | |
| Biotech | US | 2019 | |
| FoodTech | US | 2023 | |
| Biotech | Israel | 2020 | |
| Biotech | Canada | 2022 | |
| AgTech | Brazil | 2018 | |
| AgTech | US | 2021 | |
| HealthTech |  UK | 2021 | |
| Biotech | US | 2021 | |
| Biotech | US | 2022 | |
| Biotech | US | 2019 | |
| ClimateTech | US | 2026 | |
| Biotech | US | 2021 | |
| Biotech | US | 2023 | |
| FoodTech | US | 2022 | |
| Biotech | US | 2024 | |
| Industrials | US | 2019 | |
| ClimateTech | US | 2018 | |
| Biotech | US | 2023 | |
| AgTech | US | 2020 | |
| Biotech | US | 2022 | |
| AgTech | US | 2026 | |
| Biotech | US | 2026 | |
| Biotech | US | 2025 | |
| AgTech | US | 2021 | |
| Biotech | US | 2024 | |
| Biotech | US | 2020 | |
| HealthTech | US | 2021 | |
| Industrials | US | 2020 | |
| Biotech | US | 2020 | |
| HealthTech | US | 2025 | |
| HealthTech | US | 2022 |
Germany· Entry 2021US· Entry 2022US· Entry 2022US· Entry 2021US· Entry 2020US· Entry 2021US· Entry 2021US· Entry 2026US· Entry 2022US· Entry 2021US· Entry 2019US· Entry 2021US· Entry 2021US· Entry 2019US· Entry 2023US· Entry 2021UK· Entry 2021US· Entry 2021US· Entry 2022US· Entry 2019US· Entry 2026US· Entry 2021US· Entry 2023US· Entry 2022US· Entry 2024US· Entry 2019US· Entry 2018US· Entry 2023US· Entry 2020US· Entry 2022US· Entry 2026US· Entry 2026US· Entry 2025US· Entry 2021US· Entry 2024US· Entry 2020US· Entry 2021US· Entry 2020US· Entry 2020US· Entry 2025US· Entry 2022Realized
9 exits| Company | Sector | Geo | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|---|---|
| Biotech | US | 2016 | 2019 | Trade Sale | – | ||
| Biotech | US | 2023 | 2024 | IPO | – | – | |
| Biotech | US | 2022 | 2025 | Trade Sale | – | ||
| Biotech | US | 2019 | 2021 | IPO | – | – | |
| Industrials | US | 2017 | 2022 | Trade Sale | – | ||
| Biotech | US | 2021 | 2025 | – | – | – | |
| Biotech | US | 2020 | 2024 | IPO | – | – | |
| Biotech | US | 2020 | 2021 | IPO | – | – | |
| Biotech | US | 2021 | 2022 | IPO | – | – |
US· Entry 2021Saved GPs appear in your watchlist, one click from your workspace.
Investment team
Senior partners. Hand-checked from public filings and the firm's own site.
Similar firms
Other private equity firms tracked on GP Intel.
Germany·€1.8B
Germany·€1.9B
Germany·€1.6B
Germany·€1.5B
Germany·€1.5B
Germany·€2.0B
Germany·€1.4B
Germany·€1.4B
Germany·€1.4B
Germany·€1.3B
Germany·€2.3B
Germany·€1.2BGet the full picture on Leaps by Bayer.
Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.
Already a member? Sign in